| First Author | Lee HJ | Year | 2021 |
| Journal | Aging Cell | Volume | 20 |
| Issue | 3 | Pages | e13332 |
| PubMed ID | 33709472 | Mgi Jnum | J:304378 |
| Mgi Id | MGI:6511891 | Doi | 10.1111/acel.13332 |
| Citation | Lee HJ, et al. (2021) Ibrutinib modulates Abeta/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease. Aging Cell 20(3):e13332 |
| abstractText | We previously demonstrated that ibrutinib modulates LPS-induced neuroinflammation in vitro and in vivo, but its effects on the pathology of Alzheimer's disease (AD) and cognitive function have not been investigated. Here, we investigated the effects of ibrutinib in two mouse models of AD. In 5xFAD mice, ibrutinib injection significantly reduced Abeta plaque levels by promoting the non-amyloidogenic pathway of APP cleavage, decreased Abeta-induced neuroinflammatory responses, and significantly downregulated phosphorylation of tau by reducing levels of phosphorylated cyclin-dependent kinase-5 (p-CDK5). Importantly, tau-mediated neuroinflammation and tau phosphorylation were also alleviated by ibrutinib injection in PS19 mice. In 5xFAD mice, ibrutinib improved long-term memory and dendritic spine number, whereas in PS19 mice, ibrutinib did not alter short- and long-term memory but promoted dendritic spinogenesis. Interestingly, the induction of dendritic spinogenesis by ibrutinib was dependent on the phosphorylation of phosphoinositide 3-kinase (PI3K). Overall, our results suggest that ibrutinib modulates AD-associated pathology and cognitive function and may be a potential therapy for AD. |
